Ashibio says that its recent $40m funding round will facilitate its R&D efforts in bone and connective tissue disorders, with a specific focus on fibrodysplasia ossificans progressiva (FOP), as it advances andecaliximab, a discontinued asset licensed from Gilead Sciences, Inc..
The company, founded in 2022, has come out of stealth with a seed and series A financing led by MPM...







